Trifunctional antibody-cytokine fusion protein formats for tumor-targeted combination of IL-15 with IL-7 or IL-21
Authors:
Open Access
- 30 April 2025
- journal article
- immunology
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1498697
Abstract
Cytokines from the common gamma chain receptor family, such as IL-15, IL-21 and IL-7, show promise for cancer immunotherapy and have been incorporated individually into the immunocytokine approach. However, their efficacy as monotherapy is limited. Here, we investigated the molecular design of tumor-directed trifunctional antibody-cytokine fusion proteins for a combinatorial approach of IL-15 with either IL-7 or IL-21. Various fusion proteins differing in antibody format, cytokine composition and arrangement were generated and cooperative cytokine activity assessed in solution and bound to target cells. Comparative analysis revealed that formats with cytokines positioned at the N- and C-termini of the antibody were more effective than those arranged in series. For the former design, cooperative effects were observed with the scFv-based (IL-15+IL-7) trifunctional fusion protein, primarily enhancing the proliferation of naive T cells, while the scFv/Fab-based (IL-15+IL-21) trifunctional fusion proteins enhanced IFN-y release and the cytotoxic potential of T cells. Combining cytokines in the two-in-one molecule approach was principally advantageous when bound to target cells. Greater potency in inducing JAK-STAT pathway activation highlighted the importance of cytokine colocalization for cooperative receptor activation. Compared to the Fab-based (IL-15+IL-21) format, the scFv-based (IL-15+IL-21) format displayed a tendency towards higher activity in targeted and lower activity in untargeted settings, emphasizing the targeted concept. Thus, this study underscores the importance of molecular design in developing trifunctional immunocytokines and identified the scFv-based trifunctional (IL-15+IL-21) fusion protein, with the antibody in the central position, as a particularly promising candidate for further drug development.Keywords
This publication has 51 references indexed in Scilit:
- Balancing safety and efficacy: tuning the biodistribution and pharmacokinetics of cytokine immunotherapiesCurrent Opinion in Biotechnology, 2023
- A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activityNature Communications, 2022
- The use of supercytokines, immunocytokines, engager cytokines, and other synthetic cytokines in immunotherapyCellular & Molecular Immunology, 2022
- An unmet need: Harmonization of IL-7 and IL-15 combination for the ex vivo generation of minimally differentiated T cellsCellular Immunology, 2021
- Modeling cell-specific dynamics and regulation of the common gamma chain cytokinesCell Reports, 2021
- CD4+ T Cell Help Is Required for the Formation of a Cytolytic CD8+ T Cell Subset that Protects against Chronic Infection and CancerImmunity, 2019
- IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumorNature Biotechnology, 2018
- Interleukin-21: a double-edged sword with therapeutic potentialNature Reviews Drug Discovery, 2014
- Cloning and characterization of novel tumor-targeting immunocytokines based on murine IL7Journal of Biotechnology, 2011
- Harnessing the biology of IL-7 for therapeutic applicationNature Reviews Immunology, 2011